Drug and medical products company Abbott Laboratories said Tuesday it will buy Facet Biotech Corp. for about $450 million in cash, expanding the company’s access to biotechnology drugs, including a potential treatment for multiple sclerosis
Drug and medical products company Abbott Laboratories said Tuesday it will buy Facet Biotech Corp. for about $450 million in cash, expanding the company’s access to biotechnology drugs, including a potential treatment for multiple sclerosis







